| Cover - USD ($) | 12 Months Ended | ||
| Dec. 31, 2023 | Mar. 28, 2024 | Jun. 30, 2023 | |
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | BioRestorative Therapies, Inc. (the “Company”) is filing this Amendment No. 2 on Form 10-K/A (this “Amendment”) to amend the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “Original Filing”) and amended with Amendment No. 1 filed on June 11, 2024 (“Amendment No. 1”). The sole purpose of this Amendment is to supplement the Exhibits contained in Item 15(a)(3) of Part IV of the Original Filing and Amendment No. 1 to include Exhibit 4.1, which was inadvertently omitted from the Original Filing and Amendment No. 1. This Amendment is being filed as an exhibit-only filing. Except as described above, no changes have been made to the Original Filing or Amendment No. 1. This Amendment does not modify, amend, or update in any way any of the financial or other information contained in the Original Filing or Amendment No. 1. Accordingly, this Amendment should be read in conjunction with the Original Filing, Amendment No. 1 and the Company’s other filings with the SEC. Pursuant to Rule 12b-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), currently dated certifications are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act under Item 15 of Part IV hereof. Because no financial statements have been included in this Amendment and this Amendment does not contain any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2023 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2023 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-37603 | ||
| Entity Registrant Name | BIORESTORATIVE THERAPIES, INC. | ||
| Entity Central Index Key | 0001505497 | ||
| Entity Tax Identification Number | 30-1341024 | ||
| Entity Incorporation, State or Country Code | NV | ||
| Entity Address, Address Line One | 40 Marcus Drive | ||
| Entity Address, Address Line Two | Suite 1 | ||
| Entity Address, City or Town | Melville | ||
| Entity Address, State or Province | NY | ||
| Entity Address, Postal Zip Code | 11747 | ||
| City Area Code | (631) | ||
| Local Phone Number | 760-8100 | ||
| Title of 12(b) Security | Common Stock $0.0001 par value | ||
| Trading Symbol | BRTX | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 13,663,719 | ||
| Entity Bankruptcy Proceedings, Reporting Current | true | ||
| Entity Common Stock, Shares Outstanding | 6,769,919 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Auditor Firm ID | 688 | ||
| Auditor Name | Marcum LLP | ||
| Auditor Location | Marlton, New Jersey |
